298 related articles for article (PubMed ID: 2460616)
1. Biochemical profile of risperidone, a new antipsychotic.
Leysen JE; Gommeren W; Eens A; de Chaffoy de Courcelles D; Stoof JC; Janssen PA
J Pharmacol Exp Ther; 1988 Nov; 247(2):661-70. PubMed ID: 2460616
[TBL] [Abstract][Full Text] [Related]
2. In vitro and in vivo receptor binding and effects on monoamine turnover in rat brain regions of the novel antipsychotics risperidone and ocaperidone.
Leysen JE; Janssen PM; Gommeren W; Wynants J; Pauwels PJ; Janssen PA
Mol Pharmacol; 1992 Mar; 41(3):494-508. PubMed ID: 1372084
[TBL] [Abstract][Full Text] [Related]
3. Receptor-binding properties in vitro and in vivo of ritanserin: A very potent and long acting serotonin-S2 antagonist.
Leysen JE; Gommeren W; Van Gompel P; Wynants J; Janssen PF; Laduron PM
Mol Pharmacol; 1985 Jun; 27(6):600-11. PubMed ID: 2860558
[TBL] [Abstract][Full Text] [Related]
4. Pharmacology of risperidone (R 64 766), a new antipsychotic with serotonin-S2 and dopamine-D2 antagonistic properties.
Janssen PA; Niemegeers CJ; Awouters F; Schellekens KH; Megens AA; Meert TF
J Pharmacol Exp Ther; 1988 Feb; 244(2):685-93. PubMed ID: 2450200
[TBL] [Abstract][Full Text] [Related]
5. Risperidone: a novel antipsychotic with balanced serotonin-dopamine antagonism, receptor occupancy profile, and pharmacologic activity.
Leysen JE; Janssen PM; Megens AA; Schotte A
J Clin Psychiatry; 1994 May; 55 Suppl():5-12. PubMed ID: 7520908
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological profile of the new potent neuroleptic ocaperidone (R 79,598).
Megens AA; Awouters FH; Meert TF; Schellekens KH; Niemegeers CJ; Janssen PA
J Pharmacol Exp Ther; 1992 Jan; 260(1):146-59. PubMed ID: 1370538
[TBL] [Abstract][Full Text] [Related]
7. Is it possible to predict the clinical effects of neuroleptics from animal data? Part V: From haloperidol and pipamperone to risperidone.
Janssen PA; Awouters FH
Arzneimittelforschung; 1994 Mar; 44(3):269-77. PubMed ID: 7514873
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological profile of AD-5423, a novel antipsychotic with both potent dopamine-D2 and serotonin-S2 antagonist properties.
Oka M; Noda Y; Ochi Y; Furukawa K; Une T; Kurumiya S; Hino K; Karasawa T
J Pharmacol Exp Ther; 1993 Jan; 264(1):158-65. PubMed ID: 8093723
[TBL] [Abstract][Full Text] [Related]
9. Survey on the pharmacodynamics of the new antipsychotic risperidone.
Megens AA; Awouters FH; Schotte A; Meert TF; Dugovic C; Niemegeers CJ; Leysen JE
Psychopharmacology (Berl); 1994 Feb; 114(1):9-23. PubMed ID: 7531353
[TBL] [Abstract][Full Text] [Related]
10. Alniditan, a new 5-hydroxytryptamine1D agonist and migraine-abortive agent: ligand-binding properties of human 5-hydroxytryptamine1D alpha, human 5-hydroxytryptamine1D beta, and calf 5-hydroxytryptamine1D receptors investigated with [3H]5-hydroxytryptamine and [3H]alniditan.
Leysen JE; Gommeren W; Heylen L; Luyten WH; Van de Weyer I; Vanhoenacker P; Haegeman G; Schotte A; Van Gompel P; Wouters R; Lesage AS
Mol Pharmacol; 1996 Dec; 50(6):1567-80. PubMed ID: 8967979
[TBL] [Abstract][Full Text] [Related]
11. Preclinical evaluation of McN-5707 as a potential antidepressant.
Shank RP; Gardocki JF; Schneider CR; Vaught JL; Setler PE; Maryanoff BE; McComsey DF
J Pharmacol Exp Ther; 1987 Jul; 242(1):74-84. PubMed ID: 3039115
[TBL] [Abstract][Full Text] [Related]
12. Characterization of [3H]quinpirole binding to D2-like dopamine receptors in rat brain.
Levant B; Grigoriadis DE; DeSouza EB
J Pharmacol Exp Ther; 1992 Sep; 262(3):929-35. PubMed ID: 1356154
[TBL] [Abstract][Full Text] [Related]
13. Functional interaction between serotonin-S2 and dopamine-D2 neurotransmission as revealed by selective antagonism of hyper-reactivity to tryptamine and apomorphine.
Awouters F; Niemegeers CJ; Megens AA; Janssen PA
J Pharmacol Exp Ther; 1990 Sep; 254(3):945-51. PubMed ID: 1697623
[TBL] [Abstract][Full Text] [Related]
14. Neurochemical characteristics of amisulpride, an atypical dopamine D2/D3 receptor antagonist with both presynaptic and limbic selectivity.
Schoemaker H; Claustre Y; Fage D; Rouquier L; Chergui K; Curet O; Oblin A; Gonon F; Carter C; Benavides J; Scatton B
J Pharmacol Exp Ther; 1997 Jan; 280(1):83-97. PubMed ID: 8996185
[TBL] [Abstract][Full Text] [Related]
15. Stimulation by risperidone of rat prolactin secretion in vivo and in cultured pituitary cells in vitro.
Bowden CR; Voina SJ; Woestenborghs R; De Coster R; Heykants J
J Pharmacol Exp Ther; 1992 Aug; 262(2):699-706. PubMed ID: 1380082
[TBL] [Abstract][Full Text] [Related]
16. KKHA-761, a potent D3 receptor antagonist with high 5-HT1A receptor affinity, exhibits antipsychotic properties in animal models of schizophrenia.
Park WK; Jeong D; Cho H; Lee SJ; Cha MY; Pae AN; Choi KI; Koh HY; Kong JY
Pharmacol Biochem Behav; 2005 Oct; 82(2):361-72. PubMed ID: 16216322
[TBL] [Abstract][Full Text] [Related]
17. CI-1007, a dopamine partial agonist and potential antipsychotic agent. I. Neurochemical effects.
Rugsley TA; Davis MD; Akunne HC; Cooke LW; Whetzel SZ; MacKenzie RG; Shih YH; van Leeuwen DH; DeMattos SB; Georgic LM
J Pharmacol Exp Ther; 1995 Aug; 274(2):898-911. PubMed ID: 7636753
[TBL] [Abstract][Full Text] [Related]
18. Dihydrexidine, a novel full efficacy D1 dopamine receptor agonist.
Mottola DM; Brewster WK; Cook LL; Nichols DE; Mailman RB
J Pharmacol Exp Ther; 1992 Jul; 262(1):383-93. PubMed ID: 1352553
[TBL] [Abstract][Full Text] [Related]
19. Identification of nonserotonergic [3H]ketanserin binding sites associated with nerve terminals in rat brain and with platelets; relation with release of biogenic amine metabolites induced by ketanserin- and tetrabenazine-like drugs.
Leysen JE; Eens A; Gommeren W; van Gompel P; Wynants J; Janssen PA
J Pharmacol Exp Ther; 1988 Jan; 244(1):310-21. PubMed ID: 3336007
[TBL] [Abstract][Full Text] [Related]
20. [Serotonin antagonism involved in the antipsychotic effect. Confirmation with ritanserine and risperidone].
Niemegeers CJ; Awouters F; Janssen PA
Encephale; 1990; 16(2):147-51. PubMed ID: 1693560
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]